Researchers have identified SET-152, a new drug compound that reduces fat buildup in the liver by blocking a protein called PKLR through JNK inhibition. In laboratory studies and rats with diet-induced fatty liver disease, SET-152 successfully reduced hepatic fat accumulation, decreased liver stiffness, and improved disease biomarkers. According to Gram Research analysis, this compound represents a promising therapeutic strategy for metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form (MASH), though human clinical trials are still needed.
Researchers have discovered a new way to treat fatty liver disease by targeting a specific protein called PKLR using compounds that block a cellular pathway called JNK. According to Gram Research analysis, scientists tested five different drug candidates in lab cells and in rats with diet-induced fatty liver disease. The most promising candidate, called SET-152, reduced fat buildup in the liver and improved markers of liver damage. This research suggests a potential new treatment strategy for metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, which affect millions of people worldwide.
Key Statistics
A research article published in Frontiers in Pharmacology in 2026 found that five JNK-inhibiting drug compounds reduced intracellular fat accumulation in human liver cells by suppressing key fat-production proteins including PKLR, FASN, ACACA, SCD1, SREBP1-c, and ChREBP.
In a rat model of diet-induced fatty liver disease, the compound SET-152 reduced hepatic lipid accumulation, decreased liver stiffness, and improved metabolic dysfunction-associated steatotic liver disease biomarkers compared to untreated controls.
Three drug derivatives (SET-151, SET-152, and SET-162) demonstrated stronger anti-steatotic effects than the original JNK-IN-5A compound by uniquely downregulating genes involved in pyruvate metabolism, bile acid synthesis, fatty acid metabolism, and glycolysis pathways.
The Quick Take
- What they studied: Whether blocking a protein called PKLR using new drug compounds could reduce fat accumulation in liver cells and treat fatty liver disease in animals
- Who participated: Laboratory experiments used human liver cells (HepG2 cells) and rats fed a high-sugar, high-fat diet to mimic human fatty liver disease
- Key finding: Five drug candidates successfully reduced fat buildup in liver cells, with SET-152 showing the strongest effects in reducing liver fat and improving liver health markers in rats with diet-induced fatty liver disease
- What it means for you: This research identifies a promising new drug target and candidate treatment for fatty liver disease, though human clinical trials are still needed before these compounds could become available as medications
The Research Details
Researchers used a multi-step approach to develop and test new drugs for fatty liver disease. First, they used computer analysis to identify a drug compound (JNK-IN-5A) that could block a cellular pathway and reduce production of a protein called PKLR, which is linked to fatty liver disease. They then created four modified versions of this compound to potentially improve its effectiveness. The team tested all five compounds in human liver cells grown in the laboratory that had been made to accumulate excess fat, measuring how well each drug reduced fat buildup and affected genes involved in fat production. They also analyzed the genetic changes caused by each drug using advanced sequencing technology to understand how the compounds worked at a molecular level.
This research approach is important because it combines computational drug discovery with laboratory validation and animal testing, which helps identify the most promising candidates before expensive human trials. By testing multiple drug variants and analyzing their effects on genes and metabolic pathways, researchers can understand not just whether a drug works, but how it works and why some versions might be better than others. This systematic approach reduces the risk of failure in later-stage development.
The study demonstrates solid scientific methodology by using multiple validation approaches: cell-based experiments, genetic analysis, and animal models. The use of RNA sequencing and systems biology analysis provides detailed molecular understanding. However, the study is limited to laboratory and animal models; human clinical trials have not yet been conducted. The specific sample sizes for animal experiments are not detailed in the abstract, and the compounds are still in early-stage development.
What the Results Show
All five drug compounds successfully reduced fat accumulation in human liver cells by blocking key proteins involved in fat production (PKLR, FASN, ACACA, SCD1, SREBP1-c, and ChREBP). Three compounds—SET-151, SET-152, and SET-162—showed particularly strong effects and uniquely affected multiple metabolic pathways involved in fat production, glucose metabolism, and bile acid processing. In rats with diet-induced fatty liver disease, two compounds (JNK-IN-5A and SET-152) reduced the amount of fat stored in the liver, decreased liver stiffness (a sign of liver damage), and improved blood markers of liver disease. SET-152 emerged as the most promising candidate, showing the strongest anti-steatotic effects in both cell and animal models.
The genetic analysis revealed that the most effective compounds (SET-151, SET-152, SET-162) altered metabolic pathways beyond simple fat production, affecting pyruvate metabolism, bile acid synthesis, and glycolysis. This broader metabolic effect may explain why these compounds were more effective than the original JNK-IN-5A compound. Safety testing in rats showed that the compounds were well-tolerated with no significant toxicity concerns, suggesting they could be safe for further development.
This research builds on previous findings linking PKLR to fatty liver disease by identifying specific compounds that can target this protein through JNK inhibition. The use of drug derivatives to improve upon an initial compound is a standard approach in drug development. The focus on multiple metabolic pathways rather than a single target aligns with current understanding that fatty liver disease involves complex metabolic dysfunction requiring multi-targeted approaches.
This study is limited to laboratory cell cultures and animal models; no human studies have been conducted. The specific number of animals tested and detailed statistical analyses are not provided in the abstract. The compounds are still in early development stages and would require extensive additional testing for safety and efficacy in humans before clinical use. Results in animal models do not always translate to human patients. Long-term effects and potential side effects in humans remain unknown.
The Bottom Line
Based on this early-stage research, SET-152 appears to be a promising drug candidate for treating fatty liver disease and warrants further development and clinical testing. However, these findings are preliminary and should not be considered a treatment recommendation. Patients with fatty liver disease should continue following established medical advice regarding diet, exercise, and weight management while awaiting results from human clinical trials.
This research is relevant to the millions of people with metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form (MASH), as well as researchers and pharmaceutical companies developing new treatments. Healthcare providers treating fatty liver disease should monitor this research as it progresses through clinical development. People with fatty liver disease should not expect these compounds to be available as treatments in the near term.
These compounds are in early-stage development. Typically, drugs require 5-10 years of additional research and testing before becoming available to patients, including preclinical safety studies, investigational new drug applications, and multiple phases of human clinical trials.
Frequently Asked Questions
What is PKLR and why is it important for treating fatty liver disease?
PKLR is a protein linked to metabolic dysfunction-associated steatotic liver disease (MASLD). By blocking PKLR using new drug compounds, researchers can reduce the liver’s ability to produce and store excess fat, potentially treating fatty liver disease at its source.
When will SET-152 be available as a treatment for fatty liver disease?
SET-152 is still in early-stage development. Typically, drugs require 5-10 years of additional research, safety testing, and human clinical trials before becoming available to patients. No timeline for human trials has been announced.
Is this research applicable to people with NASH or MASH?
Yes, this research targets both MASLD and its more severe form, MASH (metabolic dysfunction-associated steatohepatitis). The compounds showed promise in reducing liver damage markers in animal models, suggesting potential benefit for both conditions.
What should people with fatty liver disease do right now based on this research?
Continue following proven treatments: maintain a healthy weight, reduce added sugars and saturated fats, exercise regularly, and work with your healthcare provider. Monitor this research as it progresses, but don’t expect these new drugs to be available soon.
How does blocking JNK help treat fatty liver disease?
JNK is a cellular pathway that controls PKLR and other proteins involved in fat production. By inhibiting JNK, these new drugs reduce the activity of multiple fat-producing enzymes simultaneously, providing a broader therapeutic effect than targeting a single protein.
Want to Apply This Research?
- Track liver health markers if you have fatty liver disease: monitor weight, waist circumference monthly, and record any changes in energy levels or digestive symptoms. If prescribed monitoring labs, track ALT/AST liver enzyme levels and ultrasound findings.
- Use the app to log dietary choices focusing on reducing added sugars and saturated fats, which are key drivers of fatty liver disease. Set daily goals for vegetable intake and track physical activity, as diet and exercise remain the most proven current treatments for MASLD.
- Create a long-term health dashboard tracking weight trends, dietary patterns, and any liver-related symptoms. Set quarterly reminders to discuss liver health with your healthcare provider and monitor for updates on new treatment options as they progress through clinical trials.
This research describes early-stage drug development in laboratory and animal models. These compounds have not been tested in humans and are not available as treatments. This article is for educational purposes only and should not be considered medical advice. Individuals with fatty liver disease should consult with their healthcare provider about appropriate treatment options. Do not attempt to obtain or use these experimental compounds without medical supervision. Always discuss new treatment approaches with your doctor before making changes to your health regimen.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.